A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes
Abstract
:1. Introduction
2. Experimental Section
2.1. Study Population
2.2. Radiologic Measurements and Analysis
2.2.1. Multidetector Computed Tomography Imaging Protocol and Image Analysis
2.2.2. Region of Interest (ROI) Measurements
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Conflicts of Interest
References
- Baumgart, D.C.; Carding, S.R. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007, 369, 1627–1640. [Google Scholar] [CrossRef]
- Kaser, A.; Zeissig, S.; Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28, 573–621. [Google Scholar] [CrossRef] [PubMed]
- Ordas, I.; Eckmann, L.; Talamini, M.; Baumgart, D.C.; Sandborn, W.J. Ulcerative colitis. Lancet 2012, 380, 1606–1619. [Google Scholar] [CrossRef]
- Von der Weid, P.Y.; Rainey, K.J. Review article: Lymphatic system and associated adipose tissue in the development of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2010, 32, 697–711. [Google Scholar] [CrossRef] [PubMed]
- Alexander, J.S.; Chaitanya, G.V.; Grisham, M.B.; Boktor, M. Emerging roles of lymphatics in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 2010, 1207 (Suppl. 1), E75–E85. [Google Scholar] [CrossRef] [PubMed]
- D’Alessio, S.; Tacconi, C.; Fiocchi, C.; Danese, S. Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr. Opin. Gastroenterol. 2013, 29, 608–613. [Google Scholar] [CrossRef] [PubMed]
- Lucey, B.C.; Stuhlfaut, J.W.; Soto, J.A. Mesenteric lymph nodes seen at imaging: Causes and significance. Radiographics 2005, 25, 351–365. [Google Scholar] [CrossRef] [PubMed]
- Tolan, D.J.; Greenhalgh, R.; Zealley, I.A.; Halligan, S.; Taylor, S.A. Mr enterographic manifestations of small bowel crohn disease. Radiographics 2010, 30, 367–384. [Google Scholar] [CrossRef] [PubMed]
- Kilcoyne, A.; Kaplan, J.L.; Gee, M.S. Inflammatory bowel disease imaging: Current practice and future directions. World J. Gastroenterol. 2016, 22, 917–932. [Google Scholar] [CrossRef] [PubMed]
- Patel, B.; Mottola, J.; Sahni, V.A.; Cantisani, V.; Ertruk, M.; Friedman, S.; Bellizzi, A.M.; Marcantonio, A.; Mortele, K.J. Mdct assessment of ulcerative colitis: Radiologic analysis with clinical, endoscopic, and pathologic correlation. Abdom. Imaging 2012, 37, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Deepak, P.; Bruining, D.H. Radiographical evaluation of ulcerative colitis. Gastroenterol. Rep. (Oxf) 2014, 2, 169–177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Truelove, S.C.; Witts, L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955, 2, 1041–1048. [Google Scholar] [CrossRef] [PubMed]
- Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989, 298, 82–86. [Google Scholar] [CrossRef] [PubMed]
- Kaiserling, E. Newly-formed lymph nodes in the submucosa in chronic inflammatory bowel disease. Lymphology 2001, 34, 22–29. [Google Scholar] [PubMed]
- Kaiserling, E.; Krober, S.; Geleff, S. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 2003, 36, 52–61. [Google Scholar] [PubMed]
- Rahier, J.F.; De Beauce, S.; Dubuquoy, L.; Erdual, E.; Colombel, J.F.; Jouret-Mourin, A.; Geboes, K.; Desreumaux, P. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011, 34, 533–543. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liao, S.; von der Weid, P.Y. Lymphatic system: An active pathway for immune protection. Semin. Cell Dev. Biol. 2015, 38, 83–89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ge, Y.; Li, Y.; Gong, J.; Zhu, W. Mesenteric organ lymphatics and inflammatory bowel disease. Ann. Anat. 2018, 218, 199–204. [Google Scholar] [CrossRef] [PubMed]
- Alexander, J.S.; Ganta, V.C.; Jordan, P.A.; Witte, M.H. Gastrointestinal lymphatics in health and disease. Pathophysiology 2010, 17, 315–335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cioffi, M.; Rosa, A.D.; Serao, R.; Picone, I.; Vietri, M.T. Laboratory markers in ulcerative colitis: Current insights and future advances. World J. Gastrointest. Pathophysiol. 2015, 6, 13–22. [Google Scholar] [CrossRef] [PubMed]
Active UC (n = 61) | Inactive UC (n = 39) | p | |
---|---|---|---|
Age (years) | 47 ± 16 | 46 ± 13 | 0.56 |
Male, n (%) | 40 (66) | 25 (64) | 0.88 |
Disease duration (months) | 13 (4–50) | 45 (30–77) | <0.01 |
Extent of UC, n (%) | 0.03 | ||
Distal extension | 29 (48) | 27 (69) | |
Proctitis/sigmoiditis | 8 (13) | 14 (36) | |
Left sided | 21 (35) | 13 (33) | |
Proximal extension | 32 (52) | 12 (31) | |
Extensive | 17 (28) | 8 (21) | |
Pancolitis | 15 (24) | 4 (10) | |
Treatment, n (%) | 0.12 | ||
Mesalazine alone | 33 (54) | 28 (72) | |
Immunosuppressive * | 28 (46) | 11 (28) | |
Corticosteroid | 9 (15) | 3 (8) | |
Azathioprine | 18 (29) | 7 (18) | |
Anti TNF | 1 (2) | 1 (2) |
Active UC (n = 61) | Inactive UC (n = 39) | p | |
---|---|---|---|
Hemoglobin (g/dL) | 12.5 ± 2.3 | 14.0 ± 2.1 | <0.01 |
Leucocyte count (/mm3) | 8260 (6330–11,050) | 6825 (5995–8995) | 0.02 |
Platelet count (/mm3) | 357 ± 137 | 281 ± 81 | <0.01 |
ESR (mm/h) | 23 (14–39) | 8 (5–15) | <0.01 |
CRP | 6.0 (3.3–16.6) | 3.2 (3.1–6.0) | <0.01 |
Fasting glucose | 94 (84–109) | 88.5 (84–103) | 0.42 |
BUN | 27 ± 10 | 31 ± 11 | 0.14 |
Creatinine | 0.76 ± 0.19 | 0.81 ± 0.23 | 0.32 |
ALT | 21 (16–28) | 22.5 (19–28) | 0.28 |
Albumin | 4.0 ± 0.6 | 4.4 ± 0.4 | <0.01 |
Radiological LN characteristics | |||
LN dimension (mm) | 7.0 ± 1.9 | 6.8 ± 2.9 | 0.23 |
LN attenuation (HU) | 49 (37–60) | 58 (31.5–68.5) | 0.31 |
Proximal Active Disease (n = 32) | Proximal Inactive Disease (n = 12) | Distal Active Disease (n = 29) | Distal Inactive Disease (n = 27) | |
---|---|---|---|---|
LN dimension (mm) | 7.3 ± 1.9 | 7.1 ± 2.7 | 6.8 ± 1.8 | 6.6 ± 2.9 |
LN attenuation (HU) | 47.5 (40–60) | 21 (12–60.5) | 54 (29–63) | 59 (43.5–71) |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sahin, A.; Artas, H.; Eroglu, Y.; Tunc, N.; Oguz, G.; Demirel, U.; Poyrazoglu, O.K.; Yalniz, M.; Bahcecioglu, I.H. A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes. J. Clin. Med. 2018, 7, 142. https://doi.org/10.3390/jcm7060142
Sahin A, Artas H, Eroglu Y, Tunc N, Oguz G, Demirel U, Poyrazoglu OK, Yalniz M, Bahcecioglu IH. A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes. Journal of Clinical Medicine. 2018; 7(6):142. https://doi.org/10.3390/jcm7060142
Chicago/Turabian StyleSahin, Abdurrahman, Hakan Artas, Yesim Eroglu, Nurettin Tunc, Gulcan Oguz, Ulvi Demirel, Orhan Kursat Poyrazoglu, Mehmet Yalniz, and Ibrahim Halil Bahcecioglu. 2018. "A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes" Journal of Clinical Medicine 7, no. 6: 142. https://doi.org/10.3390/jcm7060142
APA StyleSahin, A., Artas, H., Eroglu, Y., Tunc, N., Oguz, G., Demirel, U., Poyrazoglu, O. K., Yalniz, M., & Bahcecioglu, I. H. (2018). A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes. Journal of Clinical Medicine, 7(6), 142. https://doi.org/10.3390/jcm7060142